Eli Lilly (LLY) has completed its acquisition of Adverum Biotechnologies (ADVM), and with it, gains the gene therapy candidate, Ixo-vec, for wet age-related macular degeneration.
Lilly is paying $3.56 in cash per Adverum share, plus a contingent value right worth up to
